Review Article
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
Figure 5
Meta-analysis of the safety of MAbs group and HDACi group in patients with RRMM: risk ratio for at least grade 3 anemia (a), neutropenia (b), thrombocytopenia (c), and sense of fatigue (d) of MAb group and HDACi group versus their corresponding control group. āā in Figure 5(b) and Figure 5(c), which was automatically generated by Stata software, represents actually, denoting that there exists heterogeneity among studies.
(a) |
(b) |
(c) |
(d) |